Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,455 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Richard William Scalzo also recently made the following trade(s):

• On Wednesday, September 18th, Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock. The shares were sold at an average price of $34.55, for a total value of $48,024.50.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $25.73 on Friday. The stock has a market capitalization of $2.62 billion, a P/E ratio of -7.23 and a beta of 1.09. The business has a 50-day moving average of $30.39 and a two-hundred day moving average of $35.20. Dyne Therapeutics, Inc. has a fifty-two week low of $11.51 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DYN. Nisa Investment Advisors LLC grew its stake in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at about $36,000. US Bancorp DE increased its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Finally, Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth about $62,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on DYN shares. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday. They set an “outperform” rating and a $46.00 target price for the company. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Royal Bank of Canada assumed coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.